Clinical data | |
---|---|
Trade names | Zemuron, Esmeron, others |
Other names | Rocuronium bromide, [3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enyl-2,3,4,5-tetrahydropyrrol-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | Intravenous |
Drug class | Neuromuscular blocker |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | NA |
Protein binding | ~30% |
Metabolism | Some de-acetylation |
Onset of action | 60 secs[1] |
Elimination half-life | 66–80 minutes |
Duration of action | 25 to 90 mins[1][2] |
Excretion | Unchanged, in bile and urine |
Identifiers | |
| |
Chemical and physical data | |
Formula | C32H53BrN2O4 |
Molar mass | 609.690 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Rocuronium, sold under a number of brands, is a medication used to paralyze muscles for endotracheal intubation, including rapid sequence induction (RSI).[3][4] It may also be used to relax muscles during surgery and when people are on a ventilator.[3] It is given by injection into a vein.[3] A single dose begins working after about 45 to 120 seconds and lasts for 25 to 90 minutes.[1][2]
Common side effects include low blood pressure and high blood pressure.[3] Other serious side effects may include anaphylaxis and prolonged muscle weakness.[3][5] While not well studied in pregnancy, no harms have been found.[6] Breastfeeding shortly following use is likely okay.[7] Rocuronium is a neuromuscular blocker of the non-depolarizing type.[8]
Rocuronium was approved for medical use in the United States in 1994.[3] It is avaliable as a generic medication.[9][10] In the United States it costs about 40 USD for 500 mg as of 2020.[11] In the United Kingdom this amount costs the NHS about 25 pounds.[10] Rocuronium is stable at room temperature for about 12 weeks.[2]
References
edit- ^ a b c d Cite error: The named reference
WEM2020RSI
was invoked but never defined (see the help page). - ^ a b c "Succinylcholine vs. Rocuronium: Battle of the RSI Paralytics". JEMS. 14 May 2019. Archived from the original on 24 September 2020. Retrieved 28 September 2020.
- ^ a b c d e f "Rocuronium Bromide Monograph for Professionals". Drugs.com. Archived from the original on 26 June 2019. Retrieved 19 August 2020.
- ^ Tran, DT; Newton, EK; Mount, VA; Lee, JS; Wells, GA; Perry, JJ (29 October 2015). "Rocuronium versus succinylcholine for rapid sequence induction intubation". The Cochrane Database of Systematic Reviews. 10 (10): CD002788. doi:10.1002/14651858.CD002788.pub3. PMC 7104695. PMID 26512948.
- ^ Jain, Ankit; Wermuth, Harrison R.; Maani, Christopher V. (2020). "Rocuronium". StatPearls. StatPearls Publishing. Archived from the original on 29 August 2021. Retrieved 19 August 2020.
- ^ "Rocuronium (Zemuron) Use During Pregnancy". Drugs.com. Archived from the original on 3 December 2020. Retrieved 19 August 2020.
- ^ "Rocuronium". Drugs and Lactation Database (LactMed). National Library of Medicine (US). 2006. Archived from the original on 30 November 2020. Retrieved 19 August 2020.
- ^ Cite error: The named reference
WEM2020
was invoked but never defined (see the help page). - ^ "Rocuronium (Zemuron) | Davis's Drug Guide". nursing.unboundmedicine.com. Archived from the original on 13 August 2020. Retrieved 19 August 2020.
- ^ a b BNF 79. London: Pharmaceutical Press. March 2020. p. 1379. ISBN 978-0857113658.
- ^ "Rocuronium Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 10 November 2019. Retrieved 19 August 2020.